InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum

Written by Petra Hegmann on 26th February 2020. Posted in Client News.

• Previous
• Next